# The 29th Scientific Conference of the Society on NeuroImmune Pharmacology in Omaha, NE, June 8–12, 2025

**Authors:** Allison M. Andrews, Linda Chang, Rosemarie Booze, Sabita Roy, Santhi Gorantla, IIker K. Sariyer, Jerel Fields, Eliseo Eugenin, Howard E. Gendelman

PMC · DOI: 10.1515/nipt-2025-0004 · Neuroimmune Pharmacology and Therapeutics · 2025-04-10

## TL;DR

The 2025 SNIP conference in Omaha will bring together experts to discuss the latest research on neuroimmune pharmacology, focusing on drug abuse, inflammation, and brain health.

## Contribution

The conference introduces new symposia and opportunities for early-career researchers in neuroimmune pharmacology.

## Key findings

- The conference will cover topics like neurodegenerative diseases, drug targeting, and neuroinflammation.
- It emphasizes the role of the neuroimmune axis in brain function and disease.
- Events include mentorship programs and sessions on novel therapeutics and diagnostics.

## Abstract

The 29th Scientific Conference of the Society on Neuroimmune Pharmacology (SNIP) in Omaha, NE, will occur from June 8th to 11th, 2025. This four-day conference showcases world-renowned biomedical research, providing insights into the latest advancements in the intersecting fields of neuroscience, immunology, pharmacology, and virology. Presentation abstracts are organized into sections that include early career development investigators, mouse models, neurodegenerative diseases, therapeutics, substance use disorders, counseling, drug targeting, disease pathobiology, Blood-Brain Barrier integrity, educational opportunities, young investigator talks, and translational medicine. SNIP remains the sole global meeting dedicated to neuroimmune pharmacology. The focus of research centers on how the neuroimmune axis connects drug abuse, inflammation, and brain functional integrity. The conference features several plenary speakers who have made unique and significant contributions to their fields alongside renowned physician-scientists and luminaries. Symposia will include the SNIP Presidential Symposium on Pathobiology and Novel Therapies for Neurodegenerative Diseases, Ultra Long-Acting Medicines, Development and Delivery of Diagnostic and Therapeutic Biomarkers to disease regions, overcoming barriers to treating neurological disorders, neuroinflammation, and reward pathways for addiction, as well as neuron-glia interaction. All presentations are framed within the context of microbial infections, drugs of abuse, and therapeutics. Therapeutics include nanopharmacology and advances in informatics analysis of multi-omics data to decipher the complex cell and molecular interactions that underpin the function of the nervous system. SNIP member symposia and a local series of presentations will highlight outstanding talent from the University of Nebraska. Additional events include lunch with NIH program officials and a NeuroImmune Pharmacology and Therapeutics Journal dinner. The goal is to unite investigators from diverse basic, clinical, and translational fields to discuss and advance our understanding of the multifactorial impact of substance abuse, inflammation, and infections critical to human health. We aim to engage and mentor young investigators in neuroimmune pharmacology and disseminate information presented at the conference to the scientific community, the general public, and healthcare providers. Cultivating the next generation of scientists is vital to our mission. The agenda encompasses early-career investigator presentations, poster sessions, meet-the-mentors luncheons, and a special panel of junior faculty. The conference also provides an enriching environment for scientists and clinicians to share ideas, foster the next generation of scientists, and promote current disease pathobiology and therapeutics trends. Opportunities to visit the Omaha zoo will be available with guest passes. We thank Dr. Carol Swarts, the Robert Eisenberg Family, Howard Kooper, the Gendelman Family Research Endowment, Fisher Scientific, Amy Sather, and the research community for sponsoring this meeting and its exchanges.

## Full-text entities

- **Diseases:** neuroinflammation (MESH:D000090862), addiction (MESH:D019966), neurological disorders (MESH:D009461), microbial infections (MESH:D015163), Neurodegenerative Diseases (MESH:D019636), infections (MESH:D007239), inflammation (MESH:D007249)
- **Species:** Homo sapiens (human, species) [taxon 9606], Mus musculus (house mouse, species) [taxon 10090]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12041845/full.md

---
Source: https://tomesphere.com/paper/PMC12041845